SPV Therapeutics Strengthens Oncology IP Portfolio with U.S. Patent Grant

U.S. Patent No. 12,760,023 B2, granted October 13, 2026, covers a differentiated bicyclo[1.1.1]pentane (BCP)-based CDK inhibitor chemotype, complementing SPV’s CDK4/6/9 inhibitor strategy and SPV113 backup program.